Skip to main content
SpringerLink
Log in

The treatment of the rheumatological manifestations of the inflammatory bowel diseases

  • Review
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

The strong link between the bowel and the osteo-articular system is suggested by many clinical and experimental observations. However, the therapeutic approach is still empirical. For symptomatic therapy it is better to favour the use of steroids and avoid non-steroidal anti-inflammatory drugs because they may induce intestinal ulcerations and can activate inflammatory bowel disease. Second line drugs (sulfasalazine, methotrexate, azathioprine, cyclosporine and leflunomide) should be used for selected indications. In some cases (severe spondylitis, severe and persistent enthesopathy) anti-TNF-α agents (infliximab) should be considered as first line therapy. In all cases it is mandatory to select the best therapeutic option for each individual patient, considering that the optimal treatment of bowel inflammation may induce “per se” a remission of the musculo-skeletal manifestations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Orchard TR, Wordsworth BP, Jewell DP (1998) Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 42:387–391

    Article  PubMed  CAS  Google Scholar 

  2. De Keyser F, Elewaut D, De Vos M, De Vlam K, Cuvelier C, Mielants H, Veys EM (1998) Bowel inflammation and the spondyloarthropathies. Rheum Dis Clin North Am 24:785–813

    Article  PubMed  Google Scholar 

  3. Holden W, Orchard T, Wordsworth P (2003) Enteropathic arthritis. Rheum Dis Clin North Am 29:513–530

    Article  PubMed  Google Scholar 

  4. Mielants H, Veys EM, Cuvelier C, de Vos M (1988) Ileocolonscopic findings in seronegative spondyloarthropathies. Br J Rheumatol 27(Suppl 2):95–105

    PubMed  Google Scholar 

  5. Baeten D, De Keyser F, Mielants H, Veys EM (2002) Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol 16:537–549

    Article  PubMed  Google Scholar 

  6. Mielants H, Veys EM, Cuvelier C, de Vos M, Goemaere S, De Clercq L, Schotteman L, Elewaut D (1995) The evolution of spondyloarthropathies in relation to gut histology. Part: III relation between gut and joint. J Rheumatol 22:2279–2284

    PubMed  CAS  Google Scholar 

  7. Baeten D, De Keyser F, Mielants H, Veys EM (2002) Immune linkages between inflammatory bowel disease and spondyloarthropathies. Curr Opin Rheumatol 14:342–347

    Article  PubMed  Google Scholar 

  8. van Tubergen A, van der Heijde D, Anderson J, Landewé R, Dougados M, Braun J, Bellamy N, Udrea G, van der Linden S (2003) Comparison of statistically derived ASAS improvement criteria for ankylosing spondylitis with clinically relevant improvement according to an expert panel. Ann Rheum Dis 62:215–221

    Article  PubMed  Google Scholar 

  9. Barkham N, Marzo-Ortega H, McGonagle D, Emery P (2004) How to diagnose axial spondyloarthropathy early. Ann Rheum Dis 63:471–472

    Article  PubMed  CAS  Google Scholar 

  10. Smale S, Natt RS, Orchard TR, Russell AS, Bjarnason I (2001) Inflammatory bowel disease and spondyloarthropathy. Arthritis Rheum 44:2728–2736

    Article  PubMed  CAS  Google Scholar 

  11. Ward MM (1999) Health-related quality of life in ankylosing spondylitis: survey of 175 patients. Arthritis Care Res 12:247–255

    Article  PubMed  CAS  Google Scholar 

  12. van Tubergen A, CoenenJ, Landewé R, Spoorenberg A, Chorus A, Boonen A, van der Linder S, van der Heijde D (2002) Assessment of fatigue in patients with ankylosing spondylitis. A psychometric analysis. Arthrtis Care Res 47:8–16

    Article  Google Scholar 

  13. Bjarnason I, Macpherson AJS, Somasundaram S, Teahon K (1993) Non-steroidal anti-inflammatory drugs and Crohn’s disease. In: Scholmeric J, Kruis W, Goebbell H, Hoenberger W, Gross V (eds) Inflammatory bowel diseases: pathophysiology as basis of treatment. Kluwer, Lancaster, pp 208–222

    Google Scholar 

  14. Bjarnason I, Hayllar J, Macpherson AJ, Russell AS (1993) Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine. Gastroenterology 104:1832–1847

    PubMed  CAS  Google Scholar 

  15. Rampton DS, Sladen GE (1981) Relapse of ulcerative proctocolitis during treatment with NSAIDs. Postgrad Med J 57:297–299

    Article  PubMed  CAS  Google Scholar 

  16. Riley SA, Mani V, Goodman MJ, Lucas S (1990) Why do patients with ulcerative colitis relapse? Gut 31:179–183

    Article  PubMed  CAS  Google Scholar 

  17. Biancone L, Tosti C, Geremia A, Fina D, Petruzziello C, Emerenziani S, Pallone F (2004) Rofecoxib and early relapse of inflammatory bowel disease: an open-label trial. Aliment Pharmacol Ther 19:755–764

    Article  PubMed  CAS  Google Scholar 

  18. Van Tubergen A, Landewé R, van der Heijde D, Hidding A, Wolter N, Asscher M, Falkenbach A, Genth E, The HG, van der Linden S (2001) Combined Spa-exercise therapy is effective in patients with ankylosing spondylitis: a randomized controlled trial. Arthritis Care Res 45:430–438

    Article  Google Scholar 

  19. Dougados M, van der Linden S, Lerislao-Repo M, Hutfeldt B, Juhlin R, Veys E, Zeidler H, Kuien TK, Olivieri I, Dijkmans B et al (1995) Sulfasalazine in the treatment of spondyloarthropathy. A randomised, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 38:618–627

    Article  PubMed  CAS  Google Scholar 

  20. Clegg DO, Reda DJ, Weisman MH, Cush JJ, Vasey FB, Schumacher HR Jr, Budiman-Mak E, Balestra DJ, Blackburn WD, Cannon GW, Inman RD, Alepa FP, Mejias E, Cohen MR, Makkena R, Mahowald ML, Higashida J, Silverman SL, Parhami N, Buxbaum J, Haakenson CM, Ward RH, Manaster BJ, Anderson RJ, Henderson WG et al (1996) Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. Arthritis Rheum 39:2004–2012

    Article  PubMed  CAS  Google Scholar 

  21. Taggart AG, Gardiner P, McEvoy FM, Hopkins R, Bird H (1996) Which is the active moiety of sulfasalazine in ankylosing spondylitis? A randomised controlled study. Arthritis Rheum 39:1400–1405

    Article  PubMed  CAS  Google Scholar 

  22. Thomson GT, McKibbon C, Inman RD (1994) Mesalamine therapy in Reiter’s syndrome. J Rheumatol 21:570–572

    PubMed  CAS  Google Scholar 

  23. De Keyser F, Van Damme N, De Vos M, Mielants H, Veys EM (2000) Opportunities for immune modulation in the spondyloarthropathies with special reference to gut inflammation. Inflamm Res 49:47–54

    Article  PubMed  Google Scholar 

  24. Chen J, LC (2004) Methotrexate for ankylosing-spondylitis. Cochrane Database Syst Rev (3):CD004524

  25. Gonzales-Lopez L, Garcia-Gonzalez A, Vasquez-Del Mercado M, Munoz-Valle JF, Gamez-Nava JI (2004) Efficacy of methotrexate in ankylosing spondylitis. J Rheumatol 31:1568–1574

    Google Scholar 

  26. Haibel H, Rudwaleit M, Braun J, Sieper J (2005) Six months open label trial of leflunomide in active ankylosing spondylitis. Ann Rheum Dis 64:124–126

    Article  PubMed  CAS  Google Scholar 

  27. Biasi D, Carletto A, Caramaschi P, Pacor ML Maleknia T, Bambara LM (2000) Efficacy of methotrexate in the treatment of ankylosing spondylitis: a three-year open study. Clin Rheumatol 19:114–117

    Article  PubMed  CAS  Google Scholar 

  28. De Keyser F, Van Damme N, De Vos M, Mielants H, Veys EM (2000) Opportunities for immune modulation in the spondyloarthropathies with special reference to gut inflammation. Inflamm Res 49:47–54

    Article  PubMed  Google Scholar 

  29. Maksymowych WP, Jhangri GS, Fitzgerald AA, LeClercq S, Chiu P, Yan A, Skeith KJ, Aaron SL, Homik J, Davis P, Sholter D, Russell AS (2002) A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 46:766–773

    Article  PubMed  CAS  Google Scholar 

  30. Huang F, Gu J, Zhao W, Zhu J, Zhang J, Yu DT (2002) One-year open-label trial of thalidomide in ankylosing spondylitis. Arthritis Rheum 47:249–254

    Article  PubMed  CAS  Google Scholar 

  31. Bollow M, Fisher T, Reisshauer H, Backhaus M, Sieper J, Hamm B, Braun J (2000) Quantitative analyse of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis as detected by magnetic resonance imaging in spondyloarthropathies. Ann Rheum Dis 59:135–140

    Article  PubMed  CAS  Google Scholar 

  32. McCormack G, Moriarty D, O’Donoghue DP, McCormick PA, Sheahan K, Baird AW (2001) Tissue cytokine and chemokine expression in inflammatory boweldisease. Inflamm Res 50:491–495

    Article  PubMed  CAS  Google Scholar 

  33. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider M, Sorensen H, Zeidler H, Thriene W, Sieper J (2002) Treatment of active ankylosing spondylitis with infliximab: a double blind placebo controlled multicenter trial. Lancet 359:1187–1193

    Article  PubMed  CAS  Google Scholar 

  34. Gorman JD, Sack KE, Davis JC (2002) Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α. New Engl J Med 346:1349–1356

    Article  PubMed  CAS  Google Scholar 

  35. Davis JC, van der Hejide D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W (2003) Recombinant human tumor necrosis factor receptor (Etanercept) for treating ankylosing spondylitis. Arthritis Rheum 48:3230–3236

    Article  PubMed  CAS  Google Scholar 

  36. Braun J, Brandt J, Listing J, Zink A, Alten R, Baumester G, Golder W, Gromnica-Ihle E, Kellner H, Schneider M, Sorensen H, Zeidler H, Reddig J, Sieper J (2003) Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Arthritis Rheum 48:2224–2233

    Article  PubMed  CAS  Google Scholar 

  37. Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, Mola EM, Salvarani C, Sanmarti R, Sany J, Sibilia J, Sieper J, van der Linden S, Veys E, Appel AM, Fatenejad S (2004) Outcomes of multicenter randomizes clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 63:1594–1600

    Article  PubMed  CAS  Google Scholar 

  38. Van der Heijde D, Dijkmans BA, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J (2004) Efficacy and safety of infliximab in patients with ankylosing spondylitis: result of a 23-week randomized, placebo controlled trial (ASSERT). Ann Rheum Dis 52:82–591

    Google Scholar 

  39. van den Bosch F, Kruithof E, De Vos M, De Keyser F, Mielants H (2000) Crohn’s disease associated with spondyloarthropathy: effect of TNF-α blockade with infliximab on articular symptoms. Lancet 356:1821–1822

    Article  PubMed  Google Scholar 

  40. Ellman MH, Hanauer S, Sitrin M, Cohen R (2001) Crohn’s disease arthritis treated with infliximab: an open trial in four patients. J Clin Rheumatol 7:67–71

    Article  PubMed  CAS  Google Scholar 

  41. Marzo-Ortega H, McGonagle D, O’Connor P, Emery P (2003) Efficacy of etanercept for treatment of Crohn’s related spondyloarthritis but not colitis. Ann Rheum Dis 62:74–76

    Article  PubMed  CAS  Google Scholar 

  42. Kaufman I, Caspi D, Yeshurun D, Dotan I, Yaron M, Elkayam O (2004) The effect of infliximab on extraintestinal manifestations of Crohn’s disease. Rheumatol Int 12:63–66

    Google Scholar 

  43. Generini S, Giacomelli R, Fedi R, Fulminis A, Pignone A, Frieri G, Del Rosso A, Viscido A, Galletti B, Fazzi M, Tonelli F, Matucci-Cerinic M (2004) Infliximab in spondyloarthropathy associated with Crohn’s disease: an open study on the efficacy in inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis 63:1664–1669

    Article  PubMed  CAS  Google Scholar 

  44. Jarnerot G, Hertervig, Friis-Liby I, Blomquist L, Karlen P, Granno C, Vilien M, Strom M, Danielsson A, Verbaan H, Hellstrom PM, Magnuson A, Curman B (2005) Infliximab as rescue therapy in severe to moderate ulcerative colitis: a randomised, placebo-controlled study. Gastroenterology 128:1805–1811

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unit of Rheumatology, Department of Clinical and Experimental Medicine, University of Ferrara, Corso Giovecca 203, 44100, Ferrara, Italy

    Melissa Padovan, Gabriella Castellino, Marcello Govoni & Francesco Trotta

Authors
  1. Melissa Padovan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gabriella Castellino
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marcello Govoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Francesco Trotta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Melissa Padovan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Padovan, M., Castellino, G., Govoni, M. et al. The treatment of the rheumatological manifestations of the inflammatory bowel diseases. Rheumatol Int 26, 953–958 (2006). https://doi.org/10.1007/s00296-006-0148-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-006-0148-x

Keywords

Search

Navigation